Coagulation reversal agent Praxbind now being used in Brazil

17 August 2017

A new coagulation reversal agen, Praxbind (idarucizumab) from German family-owned pharmaceutical company Boehringer Ingelheim, is now being used in Brazil, following marketing clearance earlier this year.

In April, the company announced the approval of Praxbind by the Brazilian regulator ANVISA (Agência Nacional de Vigilância Sanitária; National Agency for Health Surveillance), indicated for patients in treatment with Pradaxa (dabigatran), also from Boehringer Ingelheim, in situations in which there is a necessity to reverse the anticoagulant effects of the medication.

As part of a program of expanded access, which makes available new and promising medications not yet available commercially in the market, nine Brazilian hospitals will receive Praxbind, amongst which, the Hospital São Francisco de Cardiologia da Santa Casa de Misericórdia de Porto Alegre, where the reversal agent was used for the first time in the country outside the ambience of clinical research.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK